Role of ceramide in TNF-α-induced impairment of endothelium-dependent vasorelaxation in coronary arteries

American Journal of Physiology - Heart and Circulatory Physiology

Volumn 283, Issue 5 52-5, 2002, Pages

  Zhang, David X ^a   Yi, Fu Xian ^a   Zou, Ai Ping ^a   Li, Pin Lan ^a  

^a MEDICAL COLLEGE OF WISCONSIN   (United States)

Author keywords

Free radicals; Lipids; Nitric oxide; Tumor necrosis factor

Indexed keywords

BRADYKININ; CALCIMYCIN; CERAMIDE; CYTOKINE; DESIPRAMINE; FREE RADICAL; LIPID; N(G) NITROARGININE METHYL ESTER; NITRIC OXIDE; SPHINGOMYELIN PHOSPHODIESTERASE; SUPEROXIDE; TIRON; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL TISSUE; ARTICLE; ATHEROSCLEROSIS; BLOOD VESSEL TONE; CARDIOVASCULAR DISEASE; CATTLE; CONTROLLED STUDY; CORONARY ARTERY; ENDOTHELIUM CELL; ENZYME ASSAY; INFLAMMATION; NONHUMAN; PRIORITY JOURNAL; VASCULAR ENDOTHELIUM; VASODILATATION;

EID: 0036838876     PISSN: 03636135     EISSN: None     Source Type: Journal    
DOI: 10.1152/ajpheart.00318.2002     Document Type: Article

References (69)

1. Albouz S, Le Saux F, Wenger D, Hauw JJ, and Baumann N. Modifications of sphingomyelin and phosphatidylcholine metabolism by tricyclic antidepressants and phenothiazines. Life Sci 38: 357-363, 1986.
2. Aoki N, Siegfried M, and Lefer AM. Anti-EDRF effect of tumor necrosis factor in isolated, perfused cat carotid arteries. Am J Physiol Heart Circ Physiol 256: H1509-H1512, 1989.
3. Basaran Y, Basaran MM, Babacan KF, Ener B, Okay T, Gok H, and Ozdemir M. Serum tumor necrosis factor levels in acute myocardial infarction and unstable angina pectoris. Angiology 44: 332-337, 1993.
4. Berk BC, Abe JI, Min W, Surapisitchat J, and Yan C. Endothelial atheroprotective and anti-inflammatory mechanisms. Ann NY Acad Sci 947: 93-109, 2001.
5. Bhagat K and Vallance P. Inflammatory cytokines impair endothelium-dependent dilatation in human veins in vivo. Circulation 96: 3042-3047, 1997.
6. Bhunia AK, Arai T, Bulkley G, and Chatterjee S. Lactosylceramide mediates tumor necrosis factor-alpha-induced intercellular adhesion molecule-1 (ICAM-1) expression and the adhesion of neutrophil in human umbilical vein endothelial cells. J Biol Chem 273: 34349-34357, 1998.
7. Bhunia AK, Han H, Snowden A, and Chatterjee S. Redox-regulated signaling by lactosylceramide in the proliferation of human aortic smooth muscle cells. J Biol Chem 272: 15642-15649, 1997.
8. Bielawska A, Perry DK, and Hannun YA. Determination of ceramides and diglycerides by the diglyceride kinase assay. Anal Biochem 298: 141-150, 2001.
9. Bove K, Neumann P, Gertzberg N, and Johnson A. Role of ecNOS-derived NO in mediating TNF-induced endothelial barrier dysfunction. Am J Physiol Lung Cell Mol Physiol 280: L914-L922, 2001.
10. Brian JE Jr and Faraci FM. Tumor necrosis factor-alpha-induced dilatation of cerebral arterioles. Stroke 29: 509-515, 1998.
11. Busse R and Mulsch A. Induction of nitric oxide synthase by cytokines in vascular smooth muscle cells. FEBS Lett 275: 87-90, 1990.
12. Cai H and Harrison DG. Endothelial dysfunction in cardiovascular diseases: The role of oxidant stress. Circ Res 87: 840-844, 2000.
13. Cain BS, Harken AH, and Meldrum DR. Therapeutic strategies to reduce TNF-α mediated cardiac contractile depression following ischemia and reperfusion. J Mol Cell Cardiol 31: 931-947, 1999.
14. Chatterjee S. Sphingolipids in atherosclerosis and vascular biology. Arterioscler Thromb Vasc Biol 18: 1523-1533, 1998.
15. Corda S, Laplace C, Vicaut E, and Duranteau J. Rapid reactive oxygen species production by mitochondria in endothelial cells exposed to tumor necrosis factor-α is mediated by ceramide. Am J Respir Cell Mol Biol 24: 762-768, 2001.
16. Damas P, Canivet JL, de Groote D, Vrindts Y, Albert A, Franchimont P, and Lamy M. Sepsis and serum cytokine concentrations. Crit Care Med 25: 405-412, 1997.
17. Defily DV. Control of microvascular resistance in physiological conditions and reperfusion. J Mol Cell Cardiol 30; 2547-2554, 1998.
18. Di Paola M, Cocco T, and Lorusso M. Ceramide interaction with the respiratory chain of heart mitochondria. Biochemistry 39: 6660-6668, 2000.
19. Dobrowsky RT, Werner MH, Castellino AM, Chao MV, and Hannun YA. Activation of the sphingomyelin cycle through the low-affinity neurotrophin receptor. Science 265: 1596-1599, 1994.
20. Edmunds NJ and Woodward B. Effects of tumour necrosis factor-α on the coronary circulation of the rat isolated perfused heart: A potential role for thromboxane A2 and sphingosine. Br J Pharmacol 124: 493-498, 1998.
21. Elkind MS, Cheng J, Boden-Albala B, Rundek T, Thomas J, Chen H, Rabbani LE, and Sacco RL. Tumor necrosis factor receptor levels are associated with carotid atherosclerosis. Stroke 33: 31-37, 2002.
22. Elneihoum AM, Falke P, Hedblad B, Lindgarde F, and Ohlsson K. Leukocyte activation in atherosclerosis: Correlation with risk factors. Atherosclerosis 131: 79-84, 1997.
23. Ferrari R, Bachetti T, Agnoletti L, Comini L, and Curello S. Endothelial function and dysfunction in heart failure. Eur Heart J 19: G41-G47, 1998.
24. Garcia-Ruiz C, Colell A, Mari M, Morales A, and Fernandez-Checa JC. Direct effect of ceramide on the mitochondrial electron transport chain leads to generation of reactive oxygen species. Role of mitochondrial glutathione. J Biol Chem 272: 11369-11377, 1997.
25. Griendling KK, Sorescu D, and Ushio-Fukai M. NAD(P)H oxidase: role in cardiovascular biology and disease. Circ Res 86: 494-501, 2000.
26. Gurevitch J, Frolkis I, Yuhas Y, Paz Y, Matsa M, Mohr R, and Yakirevich V. Tumor necrosis factor-α is released from the isolated heart undergoing ischemia and reperfusion. J Am Coll Cardiol 28: 247-252, 1996.
27. Hannun YA. The sphingomyelin cycle and the second messenger function of ceramide. J Biol Chem 269: 3125-3128, 1994.
28. Harada-Shiba M, Kinoshita M, Kamido H, and Shimokado K. Oxidized low density lipoprotein induces apoptosis in cultured human umbilical vein endothelial cells by common and unique mechanisms. J Biol Chem 273: 9681-9687, 1998.
29. Harrison DG. Cellular and molecular mechanisms of endothelial cell dysfunction. J Clin Invest 100: 2153-2157, 1997.
30. Hauck CR, Grassme H, Bock J, Jendrossek V, Ferlinz K, Meyer TF, and Gulbins E. Acid sphingomyelinase is involved in CEACAM receptor-mediated phagocytosis of Neisseria gonorrhoeae. FEBS Lett 478: 260-266, 2000.
31. Heba G, Krzeminski T, Porc M, Grzyb J, Ratajska A, and Dembinska-Kiec A. The time course of tumor necrosis factor-α, inducible nitric oxide synthase and vascular endothelial growth factor expression in an experimental model of chronic myocardial infarction in rats. J Vasc Res 38: 288-300, 2001.
32. Hein TW and Kuo L. LDLs impair vasomotor function of the coronary microcirculation: Role of superoxide anions. Circ Res 83: 404-414, 1998.
33. Huwiler A, Kolter T, Pfeilschifter J, and Sandhoff K. Physiology and pathophysiology of sphingolipid metabolism and signaling. Biochim Biophys Acta 1485: 63-99, 2000.
34. Johns DG, Osborn H, and Webb RC. Ceramide: A novel cell signaling mechanism for vasorelaxation. Biochem Biophys Res Commun 237: 95-97, 1997.
35. G-methyl-L-arginine inhibits tumor necrosis factor-induced hypotension: Implications for the involvement of nitric oxide. Proc Natl Acad Sci USA 87: 3629- 3632, 1990.
36. Kim F, Gallis B, and Corson MA. TNF-α inhibits flow and insulin signaling leading to NO production in aortic endothelial cells. Am J Physiol Cell Physiol 280: C1057-C1065, 2001.
37. Kim MY, Linardic C, Obeid L, and Hannun YA. Identification of sphingomyelin turnover as an effector mechanism for the action of tumor necrosis factor alpha and gamma-interferon. Specific role in cell differentiation. J Biol Chem 266: 484-489, 1991.
38. Klemm P, Warner TD, Corder R, and Vane JR. Endothelin-1 mediates coronary vasoconstriction caused by exogenous and endogenous cytokines. J Cardiovasc Pharmacol 26: S419-S421, 1995.
39. Kojima H, Nakatsubo N, Kikuchi K, Kawahara S, Kirino Y, Nagoshi H, Hirata Y, and Nagano T. Detection and imaging of nitric oxide with novel fluorescent indicators: Diaminofluoresceins. Anal Chem 70: 2446-2453, 1998.
40. Kronke M. Involvement of sphingomyelinases in TNF signaling pathways. Chem Phys Lipids 102: 157-166, 1999.
41. Lefer AM and Ma XL. Cytokines and growth factors in endothelial dysfunction. Crit Care Med 21: S9-S14, 1993.
42. Levade T, Auge N, Veldman RJ, Cuvillier O, Negre-Salvayre A, and Salvayre R. Sphingolipid mediators in cardiovascular cell biology and pathology. Circ Res 89: 957-968, 2001.
43. Li JM, Mullen AM, Yun S, Wientjes F, Brouns GY, Thrasher AJ, and Shah AM. Essential role of the NADPH oxidase subunit p47(phox) in endothelial cell superoxide production in response to phorbol ester and tumor necrosis factor-α. Circ Res 90: 143-150, 2002.
44. Ca channel activity and vascular tone in coronary arteries. Hypertension 33: 1441-1446, 1999.
45. Liu B and Hannun YA. Sphingomyelinase assay using radiolabeled substrate. Methods Enzymol 311: 164-167, 1999.
46. Liu SF, Dewar A, Crawley DE, Barnes PJ, and Evans TW. Effect of tumor necrosis factor on hypoxic pulmonary vasoconstriction. J Appl Physiol 72: 1044-1049, 1992.
47. Madge LA and Pober JS. TNF signaling in vascular endothelial cells. Exp Mol Pathol 70: 317-325, 2001.
48. Marino MW, Dunbar JD, Wu LW, Ngaiza JR, Han HM, Guo D, Matsushita M, Nairn AC, Zhang Y, Kolesnick R, Jaffe EA, and Donner DB. Inhibition of tumor necrosis factor signal transduction in endothelial cells by dimethylaminopurine. J Biol Chem 271: 28624-28629, 1996.
49. Mathias S, Younes A, Kan CC, Orlow I, Joseph C, and Kolesnick RN. Activation of the sphingomyelin signaling pathway in intact EL4 cells and in a cell-free system by IL-1 beta. Science 259: 519-522, 1993.
50. Maury CP and Teppo AM. Circulating tumour necrosis factor-alpha (cachectin) in myocardial infarction. J Intern Med 225: 333-336, 1989.
51. Meldrum DR. Tumor necrosis factor in the heart. Am J Physiol Regul Integr Comp Physiol 274: R577-R595, 1998.
52. Meldrum DR, Meng X, Dinarello CA, Ayala A, Cain BS, Shames BD, Ao L, Banerjee A, and Harken AH. Human myocardial tissue TNFα expression following acute global ischemia in vivo. J Mol Cell Cardiol 30: 1683-1689, 1998.
53. Modur V, Zimmerman GA, Prescott SM, and McIntyre TM. Endothelial cell inflammatory responses to tumor necrosis factor alpha. Ceramide-dependent and -independent mitogen-activated protein kinase cascades. J Biol Chem 271: 13094-13102, 1996.
54. Murohara T, Kugiyama K, Ohgushi M, Sugiyama S, Ohta Y, and Yasue H. Effects of sphingomyelinase and sphingosine on arterial vasomotor regulation. J Lipid Res 37: 1601-1608, 1996.
55. Nakamura M, Yoshida H, Arakawa N, Saitoh S, Satoh M, and Hiramori K. Effects of tumor necrosis factor-alpha on basal and stimulated endothelium-dependent vasomotion in human resistance vessel. J Cardiovasc Pharmacol 36: 487-492, 2000.
56. Ohanian J, Liu G, Ohanian V, and Heagerty AM. Lipid second messengers derived from glyerolipids and sphingolipids, and their role in smooth muscle function. Acta Physiol Scand 164: 533-548, 1998.
57. Okazaki T, Bielawska A, Bell RM, and Hannun YA. Role of ceramide as a lipid mediator of 1 alpha,25-dihydroxyvitamin D3-induced HL-60 cell differentiation. J Biol Chem 265: 15823- 15831, 1990.
58. Perry DK, Bielawska A, and Hannun YA. Quantitative determination of ceramide using diglyceride kinase. Methods Enzymol 312: 22-31, 2000.
59. Schutze S, Machleidt T, and Kronke M. The role of diacylglycerol and ceramide in tumor necrosis factor and interleukin-1 signal transduction. J Leukoc Biol 56: 533-541, 1994.
60. Vinten-Johansen J, Zhao ZQ, Nakamura M, Jordan JE, Ronson RS, Thourani VH, and Guyton RA. Nitric oxide and the vascular endothelium in myocardial ischemia-reperfusion injury. Ann NY Acad Sci 874: 354-370, 1999.
61. Wang P, Ba ZF, and Chaudry IH. Administration of tumor necrosis factor-α in vivo depresses endothelium-dependent relaxation. Am J Physiol Heart Circ Physiol 266: H2535-H2541, 1994.
62. Wiegmann K, Schutze S, Machleidt T, Witte D, and Kronke M. Functional dichotomy of neutral and acidic sphingomyelinases in tumor necrosis factor signaling. Cell 78: 1005-1015, 1994.
63. Xie J, Wang Y, Lippton H, Cai B, Nelson S, Kolls J, Sum. mer WR, and Greenberg SS. Tumor necrosis factor inhibits stimulated but not basal release of nitric oxide. Am Rev Respir Dis 148: 627-636, 1993.
64. Xu J, Yeh CH, Chen S, He L, Sensi SL, Canzoniero LM, Choi DW, and Hsu CY. Involvement of de novo ceramide biosynthesis in tumor necrosis factor-α/cycloheximide-induced cerebral endothelial cell death. J Biol Chem 273: 16521-16526, 1998.
65. Zhang DX, Fryer RM, Hsu AK, Zou AP, Gross GJ, Campbell WB, and Li P-L. Production and metabolism of ceramide in normal and ischemic-reperfused myocardium of rats. Basic Res Cardiol 96: 267-274, 2001.
66. Zhang DX, Zou AP, and Li PL. ADP-ribose dilates bovine coronary small arteries through apyrase- and 5′-nucleotidase-mediated metabolism. J Vasc Res 38: 64-72, 2001.
67. Zhang DX, Zou AP, and Li PL. Ceramide reduces endothelium-dependent vasorelaxation by increasing superoxide production in small bovine coronary arteries. Circ Res 88: 824-831, 2001.
68. 2+ mobilization in rat aortic smooth muscle. Eur J Pharmacol 391: 127-135, 2000.
69. i in canine cerebral vascular muscle. Am J Physiol Heart Circ Physiol 278: H1421-H1428, 2000.